Recent results from IMvigor 011 constitute the first prospective, randomized validation of a therapeutic strategy guided by circulating tumor DNA (ctDNA) status in urothelial cancer. We discuss the promise of ctDNA for guiding treatment decisions in this setting and highlight the pitfalls and further work required for wider implementation of ctDNA-based strategies.
European urology oncology. 2025 Nov 18 [Epub ahead of print]
Clara Cerrato, Morgan Rouprêt, Maria Carmen Mir
Department of Urology, Nottingham University Hospital NHS Trust, Nottingham, UK. Electronic address: ., GRC 5 Predictive Onco-Uro, Sorbonne University, Department of Urology, Pitié Salpétrière Hospital, AP-HP, Paris, France., Department of Urology, Mount Sinai Icahn School of Medicine, Elmhurst/Queens Hospitals, New York, NY, USA.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/41260941